Paradigm steht vor dem Quantensprung!

WKN: 905600   ISIN: US69900Q1085  

 

Hallo Leute,

 

da ich eher für die langzeitanlage bin, habe ich einen neuen Thread aufgemacht weil ich der Meinung bin das diese Aktien nicht nur gut zum täglichen traden ist, sondern das man hier längerfristig ein sehr gutes Geld verdienen kann.

 

 

Auf jeden Fall kommt jetzt zu einer Kapitalerhöhung und die neuen Aktien werden zum Teil weit über den jetzigen Marktpreis liegen! Es könnte sogar passieren das mit 0,10 Dollar neue Aktien gekauft werden!

Diese wichtige Nachricht kam kurz vor dem Börsenschluß in Amerika heraus.  Der  Börsenkurs hat daraufhin sofort angezogen.  

 

Ich will hier nicht pushen, aber es könnte durchaus passieren das es in kürze zu einer Kursexplosion kommen könnte! Bei W : O werde ich heute Abend in meinen eigenen Thread weiters darauf eingehen  wo ich schon Kurse von 0,10 Dollar in den nächsten 6 Monaten vorausgesagt habe. Ich bin der Meinung das hier was größeres entstehen kann und habe selber gut in diese Aktien eingekauft.

 

Ich will mich nicht ständig wiederholen, aber an der Berichtsfront zu Paradigm nimmt die Zahl der Repote (Analysen) weiter zu!

 

Research Reports Get Research Reports for:

RECENT REPORTS Released Contributor Author Title Pages Price 28-Feb-2006 Reuters Investment Profile N/A Paradigm Medical Industries, Inc.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 11 $20 27-Feb-2006 Pechala's Reports Lubomir Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 2-weeks forecast 1 $10 27-Feb-2006 Pechala's Reports Frantisek Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 12-months forecast 1 $15 27-Feb-2006 Wright Reports N/A A textual analysis of Paradigm Medical Industries, Inc.'s financial statements, including company description and recent stock performance, versus PharmaNetics, Inc., International Isotopes Inc and Hemosense, Inc.. 0 $25 27-Feb-2006 ValuEngine, Inc. N/A ValuEngine Industry Report for HOSPITAL SUPPLIES 18 $49

 

 

 

 

Press Release Source: Paradigm Medical Industries, Inc.


Paradigm Medical Completes $1.5-Million Financing
Wednesday March 1, 3:31 pm ET


SALT LAKE CITY--(BUSINESS WIRE)--March 1, 2006--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) today announced it has completed the sale of $1.5 million in secured convertible notes, through Laidlaw & Co. (UK) of New York City, and an institutional investor. The notes are to purchased by the investors in three traunches of $500,000 each. Paradigm Medical received the first traunche upon signing definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration.
ADVERTISEMENT


"Additional capital is needed at this point to provide the Company will adequate funds to expand global sales and marketing programs, especially for the P60 Ultrasound BioMicroscope," said Paradigm Medical's Chief Executive Officer, Raymond P.L. Cannefax. "Moreover, we will now have adequate funds to purchase additional inventory to satisfy expected strong customer demand for all of our products."

The notes are due three years after issuance and are secured by Paradigm Medical's assets, including inventory, accounts payable and intellectual property. The notes are convertible into shares of the Company's common stock at anytime during their term. The conversion price is equal to the lesser of (a) $0.02 per share or (b) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%.

Interest on the notes is payable at 8% per year, payable quarterly in cash, with six-months of interest payable up front. The notes are callable, with prepayment allowed at any time that the price of Paradigm Medical's stock is $0.10 per share or less.

In addition, Paradigm Medical is required to issue warrants to the investors to acquire an aggregate of 12 million shares of the Company's common stock, at an exercise price of $0.10 per share. The warrants will have a five-year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants.

Paradigm Medical is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date.

Paradigm Medical Industries, Inc., currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company's corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.



Contact:
Paradigm Medical Industries, Inc.
Raymond P.L. Cannefax, CEO, 801-977-8970

--------------------------------------------------
Source: Paradigm Medical Industries, Inc.

 

Bin neuling und hab ne Frage wieso hat die aktie so starke kursschwankungen. 50 % plus, am nächsten tag 25,93% minus????? und was glauben sie was die aktie in den nächsten tagen macht. will vielleicht investieren, aber sehe der ganzen sache noch etwas kritisch entgegen!!! :-)
für paar kurze info´s wär ich sehr dankbar
mfg
neuling83  

Wenn man bedenkt das diese Aktie bis mitte Dezember 2005 praktisch am Boden war, dann hat sie jetzt aber eine mächtige Performance gemacht. Die ersten die eingestiegen sind waren nun mal die Trader und Zocker. Eine gefestigte Anlegerschicht die längerfristig die Aktie hält gibt es nur wenige. Und wer bei 0,002 bis 0,01 eingestiegen ist der realisiert sowieso und viele andere nehmen die Gelegneheit war das durch traden  am Tag allein durchaus zweistellige Gewinne zu machen sind. Gibt es gute Nachrichten aus dem Unternehmen wie vorgestern dann geht es im nach oben. Da Paradigm mit knapp über 1 Millionen Dollar bewertet ist und die Geschichte wieder zu laufen beginnt ist es nur eine Frage der Zeit wann der nächste Kursschub kommt!

 

 

P60 UBM The next generation of Ultrasonic Biomicroscope. Provides unprecedented image accuracy and flexibility with 12.5MHz, 20MHz, 35MHz and 50MHz probes. Full Sulcus-to-Sulcus imaging Industry leading water path probe High resolution still image and live video capture Fully network ready Flexibility to do the exams you want. Four probe choices, single degree control of sweep angle and the easiest water path probe in the industry, gives you the power and flexibility to see exactly what you need to.  From full sulcus-to-sulcus measurements to detailed anatomy of the posterior chamber, the P60 provides the clarity of images and resolution you demand. User Friendly Operation A custom user interface minimizes training time with easy to use icons, and superior features including dual calipers, complete on-screen annotation, pre/post processing capabilities, as well as zoom and pan features for optimal positioning for viewing suspicious areas. Built upon the industry standard Windows XP operating systems, the P60 provides exceptional platform stability and ease of use as well as full network capabilities to transfer and save patient images and videos. Display Functions: Dual Calipers Angle Measurement Area Measurement Area Zoom Image Capture: JPG Photo Format AVI Movie Format Image Storage: 80 GB IDE Hard Drive DVD CD-R/W Drive

 

seit 09:03 keine kursänderung( - 15%)!!! Was ist eigentlich ein OTCBB wert kann mir da mal einer weiterhelfen??? und kein umsatz in frankfurt, so wie das aussieht!!!  

Die Handelsorte in Deutschland sind nur Nebenschauplätze und damit fast bedeutungslos!

Nachfolgender Link zeigt den Kurs in Amerika an. Der Börsenhandel ist um 15:30Uhr bis 22:00Uhr nach unserer Zeit!

http://de.finance.yahoo.com/q?s=PMED.OB  

RECENT REPORTS

Released Contributor Author Title Pages Price 6-Mar-2006 Pechala's Reports Lubomir Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 2-weeks forecast 1 $10 6-Mar-2006 Wright Reports N/A A textual analysis of Paradigm Medical Industries, Inc.'s financial statements, including company description and recent stock performance, versus PharmaNetics, Inc., International Isotopes Inc and Hemosense, Inc.. 0 $25 6-Mar-2006 ValuEngine, Inc. N/A ValuEngine Industry Report for HOSPITAL SUPPLIES 18 $49 28-Feb-2006 Reuters Investment Profile N/A Paradigm Medical Industries, Inc.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 11 $20 27-Feb-2006 Pechala's Reports Frantisek Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 12-months forecast 1 $15

 

immer noch überzeugt von deinem Lang-Frist-Investment? ;-)  

215. Kursexplosion von über 700% wegen der

Knappschaftsk.

08.02.07 09:25

nachfolgende Nachricht! Wer schon drin ist kann seit gestern mit mir süffisant lachen und alle hier haben es seit einen halben Jahr gewußt das in China was im Busche ist!   Press Release Source: Paradigm Medical Industries, Inc. Paradigm Medical Receives FDA Approval for New-Generation Ultrasound Devices Wednesday February 7, 9:04 am ET   Collaboration with China's MEDA results in development of new array of devices ready to meet global market needs SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, disclosed today it has received U.S. Food and Drug Administration (FDA) approval to market a new generation of Ultrasound devices. The products were developed through a collaboration with MEDA Co. Ltd., one of China's leading developers and manufacturers of ultrasound devices. The collaboration was formed in June 2006. ADVERTISEMENT The new devices were unveiled at the recent American Academy of Ophthalmology (AAO) Convention, and have already received orders internationally. "The FDA's approval of our 510(k) application will result in an immediate, stepped-up marketing campaign in the U.S. and Canada," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "The Company has already built inventories based on strong international demand and anticipated U.S. regulatory approval." The new devices include the P2000 A-Scan (used to measure axial length of the eye); P2200 Pachymeter (used for measuring corneal thickness); P2500 A-Scan/Pachymeter (a combination of the two stand-alone devices); P2700 AB/Scan (an ultrasound imaging device for detecting abnormalities within the eye); and P37-II (a more advanced AB/Scan used to provide portability for ophthalmology veterinary applications). "We believe the P37-II will set the new gold standard for AB/Scan in the industry," Mr. Cannefax noted. "FDA approval for use of these devices and the recent operations management reorganization we implemented at the beginning of this year will have a favorable effect on our performance in 2007 and beyond," Mr. Cannefax added. "The Company clearly has become one of the leading, multi-product Ultrasound device producers in the world." Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8900 or visit us at www.paradigm-medical.com. This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements. Contact: Paradigm Medical Industries, Inc. Raymond Cannefax, CEO, 801-977-8970 -------------------------------------------------- Source: Paradigm Medical Industries, Inc.

 

 

nur, verstehe ich nicht, wer hier noch zu 5 Cents verkauft. Mir soll s recht sein, bis 20 Cents kann man gut einsammeln.  

man kann immer Gewinne realisieren und das ist an der Börse ganz normal! Die Zitterigen verkaufen bereits seit gestern und ärgern sich dann halt grün und blau! Ich bin selber auch gerade knapp über ein Jahr dabei und werde auch mal zwischendurch verkaufen und wieder kaufen, den ich werde auf keinen Fall meinen Gewinn mit dem Finanzamt im Jahr 2009 teilen und mich verarschen lassen.

MfG

Knappschaftskassen  

Du bis 20 Cent einsammeln willst, was erwartest Du den so für einen Kurs?? Ich kann mir sehr gut vorstellen, das es auch hier Gewinnmitnahmen gibt-von Leuten denen das einfach zu heiß wird. Also worauf gründt Dein Glauben bis 0,20€ eizusammeln?? Vielleicht überzeugt es ja auch andere...  

... ich realisiere auch bei vielen Werten unterjährig schnell Gewinne, wenn s mir sinnvoll erscheint. Aber hier kaufe ich gerade noch gut nach. Hier ist noch viel Luft nach oben. Bis 25 Cents geht s bestimmt noch, denn der Kurs muss sich a. von seinem gnadenlosen Abverkauf im letzten Jahr erholen und b. muss er noch die guten News einspeisen, sowie c. der Wert wird jetzt erstmals vielen bekannt, die sehen hier eine gute Gelegenheit noch äußerst günstig einzusteigen. Aus diesen 3 Gründen heraus (und auch noch vielen weiteren) kaufe ich jetzt noch kräftig nach und danke jedem, der verkauft, um ein paar % Gewinn zu realisieren. ... die, die gestern verkauft haben, ärgern sich heute schwarz, diejenigen, die heute verkaufen, können sie beim schwarzärgern locker einreihen ;-)  

Paradigm Medical Industries Outlines Plan to Achieve Profitability, Positive Cash Flow
Friday October 26, 8:51 am ET


SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries’ (OTCBB: PMED.OB/PMEDW.OB) Chief Executive Officer, Raymond Cannefax, today outlined the Company’s plan to achieve profitability and positive cash flow in a special report to shareholders. Following is the complete text of Mr. Cannefax’s Letter to Shareholders

October 26, 2007

Dear Shareholder:

While 2007 results won’t be finalized for several more months, and our preliminary budgeting process has only just begun, the Company believes now is an appropriate time to communicate its progress and plans for the future.

Paradigm Medical Industries has been through turbulent times during the last few years. And much has happened in the last 20 months, since I was named Chief Executive Officer. Further, 2007 has been a year of major transition for the Company.

My message to you today is we have met many challenges and obstacles and are now poised to make substantial progress in the Company’s major goals of reaching profitability and consistent positive cash flow and enhancing shareholder value.

Hidden within the Company’s most recent quarterly financial results are several “pluses” that provide optimism for Paradigm Medical’s strategies, goals, and commitment. Specifically:

(1) We have substantially reduced the Company’s operating expenses without sacrificing quality and have improved on-time delivery. During the last five years, we have reduced the Company’s annual operating expenses by $9.5 million.

(2) We have refocused and reformulated the Company’s product portfolio into high-margin, fast-growing proprietary products. Paradigm Medical is clearly the most unique, full-service provider of Ultrasound devices to the ophthalmic industry.

(3) We have become more globally oriented with our U.S. and international regulatory-approved products. And we have already established foot prints in the fastest-growing regions of the world, namely Asia and East Europe. A major part of this success has been the establishment of partnerships with leading developers and producers of ultrasound devices like China’s MEDA Co. Ltd., and new-generation software with innovative companies like Reliacon Global (San Ramon, CA).

(4) We have resolved long-standing litigation matters without jeopardizing the Company’s financial and operational structure.

(5) We have strengthened the Company’s financial structure with the completion of several fundings, completed in 2005 and 2006, that have allowed us to upgrade our facilities and further advance our research and development programs.

(6) Organizationally, we now have a professional management team in place that is dedicated and capable of achieving the corporate strategy with a viable business model that compliments the Company’s strengths. And we have, this year, significantly upgraded our global sales and marketing efforts to allow us to move aggressively into the “growth” phase of our matrix.

Our financial results for 2007 will be relatively flat, compared with the year-ago period. Our revenues will be stable, and our operating loss will widen slightly. Clearly, that is unacceptable. Nonetheless, during a year when “uncontrollable” costs--such as higher raw material and energy bills--soared, and we incurred significant expense (some one-time) on a global launching of our new-generation P60 Ultrasound BioMicroscope (UBM), as well as considerable management time in resolving financial and legal issues, the Company made substantial progress toward reaching some short-term and intermediate-term goals.

Since 2002, the Company has reduced its operating expense by $9.5 million. In 2007, such expense will be somewhat higher than a year ago. However, a good part of the increase reflects higher costs associated with launching the P60 (including costs in receiving U.S. and international regulatory approvals) and dramatically expanding and repositioning marketing and distribution channels.

Since 2002, the Company improved its gross profit margin from 21.6% to more than 50%. Again, our margin will be somewhat lower in 2007 than a year ago. The major factor in the decline reflects lower revenues—as we reposition our portfolio toward higher-margin, proprietary products—and higher fixed and variable costs (especially energy).

The results—and rewards—for our actions are expected to be more visible in 2008 and beyond.

Specifically, the Company will be entering a fast-track path in revenue and margin growth. By the end of 2008, our goal is to be at an annualized revenue run-rate of $4 million. We believe gross profit margin will be at least 50% (likely higher), which would result in gross profit of $2 million.

Our indirect expense (e.g., selling, general, administrative, and research and development costs) will likely approximate $2 million. The “bottom line” for us is break even. This will mark a dramatic change in our financial performance, where losses have exceeded $1.0-3.4 million annually during the last few years. Management’s ability to control costs and improve operating margins could enhance the 2008 results.

More importantly, our goal is to be slightly cash flow positive by the end of 2008. Again, this will reflect a dramatic improvement from our recent year “negative” cash flows. We view our cash flow performance as one of the true benchmarks of determining the success of our corporate goals.

During the next 24 months the Company’s goal is to reach annualized sales of $5 million, and gross profit of $2.75 million. Management is committed to maintaining an indirect expense level of $2.5 million during that timeframe. At such performance levels, Paradigm Medical would generate a modest profit from operations and achieve consistently positive cash flow.

Is the goal “reasonable?” We believe so. More importantly, is it “achievable?”

Barring unforeseen external events, management believes the successful launch and global growth of our new-generation Ultrasound devices, coupled with a rededication to our Blood Flow Analyzer™ and the introduction of at least six new product offerings could bolster the base sales level and help expand the Company’s gross profit margin by several basis points.

Paradigm Medical has already achieved substantial reduction in its operating expenses and has isolated areas for additional savings. These can be achieved without penalizing the integrity of our operations. And the higher costs associated with expanding our global sales team and efforts will be offset by the higher revenues and margins we are projecting.

Too often, programs aimed at substantially reducing expenses underscore a company’s maturing and subsequent decline. This is not the case at Paradigm Medical. Reducing expense was a starting point in our strategy of growth, not a stopgap approach to combat complacency. Our manufacturing efficiency has made a quantum leap during the last 18-24 months. Our on-spec and on-time delivery performance has been outstanding.

We have successfully launched a new generation of proprietary devices and carefully scrutinized our product mix. We are more product focused and performance oriented. We believe we are able to meet the challenges ahead and reward our patient shareholders and customers and our outstanding and loyal employees.

Sincerely,

Raymond Cannefax

President and Chief Executive Officer

Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed “The UBM Company” (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.



Contact:
Paradigm Medical Industries, Inc.
Raymond Cannefax, CEO
801-977-8970

 

Paradigm Medical Industries Completes $1 Million Financing

Last update: 2:58 p.m. EST Jan. 2, 2008
PrintPrint EmailE-mail Subscribe to RSSRSS DisableDisable Live Quotes
SALT LAKE CITY, Jan 02, 2008 (BUSINESS WIRE) -- Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), the leader in glaucoma diagnostic and management devices, today announced it has completed the funding of $1 million through a group of institutional investors, headed by NIR Group (New York). A significant portion of the proceeds will be used to fund the introduction, marketing and distribution of new ophthalmic instruments and systems the Company plans to launch during the first half of 2008.
"We will also use proceeds to grow our domestic sales force, to increase direct and distributor sales force training, and to increase inventories," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "Marketing our redesigned LD 400 Visual Fields and Blood Flow Analyzer(TM) (BFA) products and introducing new devices and systems into the ophthalmic market is one of our primary areas of focus in 2008."
Mr. Cannefax noted the Company already is filling a significant order for LD 400s for one of the largest optical chains in the United Kingdom, and has written commitments for additional LD 400 Perimeters from the same chain. "We had a threefold increase in our sales organization in late 2007 and will have a presence in additional metropolitan areas. The new funding will allow us to introduce new and updated diagnostic products and have a trained and highly competent sales force to market and distribute them in 2008," Mr. Cannefax added.
The funding involves the purchase of $1,000,000 in secured convertible notes by the investing group. The notes are to be purchased in traunches, with the first traunche of $250,000 and then monthly traunches of $100,000 each until a total of $1,000,000 in notes have been purchased. Paradigm Medical received the first $250,000 upon the signing of definitive agreements on December 24, 2007. The Company also is required to issue warrants to the noteholders to purchase a total of 15,000,000 shares of common stock at an exercise price of $0.001 per share.
Under the terms of the notes, the unpaid principal balance on the notes, together with accrued interest at 8% per annum, is due in three years from the date of issuance. The notes are also convertible by the noteholders at any time into shares of common stock. The conversion price of the notes is equal to the lesser of (i) $0.02 and (ii) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 50%.
Paradigm Medical Industries, Inc., is the leader in Ultrasound devices, and glaucoma detection and management products.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
SOURCE: Paradigm Medical Industries, Inc.  

Paradigm lebt ... und scheint sich auf zu alten Höhen zu schwingen ... mit der Finanzierung können die Verkäufe nun endlich auf ein solides Fundament gehoben werden und so mit kräftig angekurbelt werden.
Die Zusammenarbeit mit den Chinesen und die gute Qualität sollten genügend Phantasie beinhalten ... nun müssen die Produkte "nur noch" bekannter werden!  

Hallo zusammen. Weiss jemand, warum die Papiere gestern in USA so abgeschmiert sind ?
Gut, bei dem Kurs !!!! kann man nicht mehr von abschmieren reden, aber gab es irgendeine News oder ähnliches.
Falls jemand was weiß, bitte mal posten.
Danke  

Paradigm Medical Industries Introduces Advances on the LD400 Full-Field Autoperimetry System
Wednesday March 5, 4:42 pm ET


SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB - News), a leader in glaucoma diagnostic and management devices, is introducing new advance developments to the Paradigm-Dicon LD400 full-field autoperimetry system. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
ADVERTISEMENT


“The Company has redesigned what we believe to be the industry’s superior autoperimeter,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. “Demand for our proprietary Paradigm-Dicon LD400 product continues to be extremely high in the U.S. and globally, and this updated product incorporates all the changes the medical profession has requested. We believe we are also broadening the market for autoperimeters.

“The kinetic fixation feature of the LD400 Autoperimeter is unique and exclusive to perimetry and offers full kinetic fixation for greater reliability, improved test results and patient comfort,” Mr. Cannefax added. “Kinetic fixation reduces patient fatigue and increases patient interest resulting in higher exam accuracy. The Paradigm-Dicon LD400 provides the highest standard of care from a full-field autoperimeter.”

New developments to the LD400 include redesigning the existing software, assuring device compatibility with a variety of printers and making the device fully networkable. All connections will be through USB ports. The patient data base will be similar to the Paradigm P60 Ultrasound BioMicroscope (UBM) and the printed examination reports will be grayscale, making them much easier to read.

Warum der Kurs jetzt einbrach, weiß ich auch nicht. Hört sich eher positiv an. Vielleicht erwartet man jetzt erhöhte Kosten.  

Danke für die schnelle Antwort. Das Argument mit den höheren Kosten ist sinnvoll. Die Aussichten sehe ich auch als positiv. Die Aktie bleibt im Depot, denn verkaufen lohnt sich eh nicht. Macht einen sehr langen Winterschlaf.Vielleicht sehen wir in den nächsten 2 - 3 Jahren ja mal wieder eine 1 vor dem Komma :-).
Auf steigende Kurse.
Paddybroker
 

ich bin da eher skeptisch. Langfristig behalte ich die auf keinen Fall. Nach der Millionenfinanzierung Anfang des Jahres spekuliere ich einfach darauf, dass die Finanziers mit paar guten News den Kurs nach oben jubeln, und sei es nur für paar Tage. Sollte das eintreffen, bin ich draußen. Langfristig OTC-Werte halten hat mich verdammt viel Geld gekostet.  

Hallo wolfsburgo,

das mit dem Winterschlaf war nicht ganz ernst gemeint. Schau Dir aber doch mal die Entwicklung seit letztem Jahr März an. Ging kontinuierlich bergab bzw. dann nur noch parallel. Wie Du schon angemerkt hast, hoffe ich auch, daß der Kurs nach oben gejubelt wird und dann bin auch raus. Sollte sich aber der Kursverlauf fortsetzen wie bisher, dann kann man ja eigentlich nur drinbleiben und hoffen.
Wir werden sehen.
Paddybroker  

March 11, 2008 - 9:37 AM EDT

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

PMED 0.0008 0.0001

Today 5d 1m 3m 1y 5y 10y



Paradigm Medical Industries to Introduce Early Glaucoma Detection Device at ASCRS Conference
Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), said today it will introduce the Glaid-PERG electrophysiology instrument for the early detection of glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, IL, next month.

“All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. The Company signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the Glaid-PERG instrument earlier this year.

After many years of clinical studies at major U.S. and European glaucoma centers, as well as at universities and research centers, the Glaid-PERG has proven to provide high test repeatability and a high level of accuracy. Ongoing research is indicating testing application for ocular ailments other than glaucoma.

“We are excited about the impact the new instrument will have—not only in our industry, but in medical benefits to those who will be diagnosed early as glaucoma suspects,” Mr. Cannefax added. “Early diagnosis will help reduce vision loss and help preserve sight. This is a logical progression in the early detection of glaucoma, the world’s major contributor to vision loss.”

Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.

“The introduction of these two devices is further indication of our Company’s leading technology in eye care,” Mr. Cannefax noted. “It is all part of our ‘Continuous Improvement’ commitment.”

Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Paradigm Medical Industries, Inc.
Joy Roop, 801-977-8970
www.paradigm-medical.com



Source: Business Wire (March 11, 2008 - 9:37 AM EDT)

News by QuoteMedia
www.quotemedia.com
 

Hallo zusammen. Was bringen die News ? Ist das nur mal wieder ein kleines Strohfeuer oder werden wir jetzt endlich mal höhere Kurse sehen? Immerhin tut sich mal was bei dem Laden. Die News hören sich ja soweit ganz gut an und ich hoffe mal, daß die Firma endlich ein paar mehr Aufträge an Land zieht. Bleibt abzuwarten, ob sich das Geschäft nachhaltig verbessert. Also lauf Kurs, lauf zu neuen oder eher alten Höhen :-)  

soll ein Shareholder-Meeting stattfinden. Ich setze auf weitere Good-News in den nächsten Wochen und stark steigende Kurse. Und wenn dann mein Kursziel erreicht ist, bin ich draußen.